title: Therapy in childhood acute nonlymphocytic leukemia (ANLL). Evolution of current concepts of chemotherapy.
abstract: Chemotherapy remains the major treatment modality in childhood acute nonlymphocytic leukemia (ANLL). Current remission induction rates range from 60% to 80%; but even with the improved rate of response to therapy, the median duration of remission has seldom exceeded 1 year. On the other hand, an increasing number of children with ANLL who were treated with intensive induction and maintenance chemotherapy regimens for a prescribed period followed by discontinuation of therapy are remaining in remission. The evolution of present-day chemotherapy approaches to childhood ANLL are reviewed in this article.
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001215:Asparaginase / Q000627:therapeutic use; D001380:Azauridine / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D013866:Thioguanine / Q000627:therapeutic use; D013868:Thioinosine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D003561:Cytarabine; D013868:Thioinosine; D014750:Vincristine; D001380:Azauridine; D003520:Cyclophosphamide; D001215:Asparaginase; D013866:Thioguanine; D011241:Prednisone; D003630:Daunorubicin